Kura Oncology price target raised to $30 from $29 at BofA

BofA analyst Jason Zemansky raised the firm’s price target on Kura Oncology (KURA) to $30 from $29 and keeps a Buy rating on the shares. The FDA approval of Kura’s ziftomenib as “Komzifti” is “a watershed moment for the company,” the analyst tells investors. Following the update, the firm increased odds of success for Komzifti approval to 100% while also adjusting sales to reflect about one month for Komzifti to roll out, driving its revised target.